| Target Price | $35.70 | 
| Price | $29.65 | 
| Potential | 
      
            
    
      
    
  20.40%
     register free of charge | 
| Number of Estimates | 16 | 
| 16 Analysts have issued a price target Travere Therapeutics Inc 2026 .
        The average Travere Therapeutics Inc target price is $35.70.
        This is 
       
    
      
    
  20.40%
     register free of charge 
                $49.35 
    
      
    
  66.44%
     register free of charge 
                $25.25 
    
      
    
  14.84%
     register free of charge | |
| A rating was issued by 21 analysts: 18 Analysts recommend Travere Therapeutics Inc to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Travere Therapeutics Inc stock has an average upside potential 2026 of 
       
    
      
    
  20.40%
     register free of charge | 
| Dec '24 | 2025 Estimates | |
|---|---|---|
| Revenue Million $ | 233.18 | 429.33 | 
| 60.55% | 84.12% | |
| EBITDA Margin | -91.97% | -15.37% | 
| 60.77% | 83.29% | |
| Net Margin | -137.90% | -24.71% | 
| 79.79% | 82.08% | 
17 Analysts have issued a sales forecast Travere Therapeutics Inc 2025 . The average Travere Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Travere Therapeutics Inc EBITDA forecast 2025. The average Travere Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Travere Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Travere Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 | 2025 Estimates | |
|---|---|---|
| Earnings Per Share $ | -4.06 | -1.19 | 
| 172.48% | 70.69% | |
| P/E | negative | |
| EV/Sales | 6.30 | 
16 Analysts have issued a Travere Therapeutics Inc forecast for earnings per share. The average Travere Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Travere Therapeutics Inc...
| Analyst | Rating | Action | Date | 
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Sep 19 2025 | 
| Stifel | Locked ➜ Locked | Locked | Sep 12 2025 | 
| Wells Fargo | Locked ➜ Locked | Locked | Sep 11 2025 | 
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Sep 10 2025 | 
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Sep 03 2025 | 
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Aug 28 2025 | 
| Wedbush | Locked ➜ Locked | Locked | Aug 07 2025 | 
| Analyst Rating | Date | 
|---|---|
| Locked 
            HC Wainwright & Co.:
             Locked ➜ Locked | Sep 19 2025 | 
| Locked 
            Stifel:
             Locked ➜ Locked | Sep 12 2025 | 
| Locked 
            Wells Fargo:
             Locked ➜ Locked | Sep 11 2025 | 
| Locked 
            HC Wainwright & Co.:
             Locked ➜ Locked | Sep 10 2025 | 
| Locked 
            HC Wainwright & Co.:
             Locked ➜ Locked | Sep 03 2025 | 
| Locked 
            HC Wainwright & Co.:
             Locked ➜ Locked | Aug 28 2025 | 
| Locked 
            Wedbush:
             Locked ➜ Locked | Aug 07 2025 | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


